• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Functional Materials >Dual-Stimuli-Responsive Cut Microbiota-Targeting Berberine-CS/PT-NPs Improved Metabolic Status in Obese Hamsters
【24h】

Dual-Stimuli-Responsive Cut Microbiota-Targeting Berberine-CS/PT-NPs Improved Metabolic Status in Obese Hamsters

机译：双刺激响应切微生物群靶向小ber碱CS / PT-NPs改善了肥胖仓鼠的代谢状态。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gut dysbiosis has been found to be involved in the pathogenesis of energy metabolic disorders and might be a new strategy for these ailments. Berberine (BBR), a botanical medicine, shows therapeutic efficacy in patients with metabolic diseases. Numerous reports have shown BBR's modulating effect on gut microbiota, opening a new avenue to understand BBR's mechanism. In this study, a colon-specific delivery system, BBR-CS/PT-NP, is investigated by the assembly of pH/gut microflora dual stimuli-responsive nanoparticles for enhancing the interaction between BBR and gut microbiota. After oral administration, the delivering system remains stable in the stomach and small intestine, followed by a burst release of BBR after reaching the colon segment rich in intestinal bacteria. The enzymes produced by bacteria degrade the nanoparticle, causing direct exposure of BBR to gut microbiota. In the high fat diet-induced obese hamsters, BBR-CS/PT-NP intervention inhibits weight-gain and fat deposition, decreases plasma lipids and glucose levels, improves inflammation condition and insulin resistance, alleviates hepatic steatosis, at a level significantly higher than the pure BBR does. The mechanisms might be attributable to the enhanced interaction between BBR and the gut flora. The results provide a novel proof-of-concept for drug delivery targeting gut microbiota to ameliorate metabolic disorders.
机译：已发现肠道营养不良与能量代谢紊乱的发病机制有关，可能是这些疾病的新策略。小ber碱（BBR）是一种植物性药物，在患有代谢性疾病的患者中显示出治疗功效。大量报道表明BBR对肠道菌群的调节作用，为了解BBR的机制开辟了一条新途径。在这项研究中，通过pH /肠道菌群双重刺激响应纳米粒子的组装来研究结肠特异性递送系统BBR-CS / PT-NP，以增强BBR与肠道菌群之间的相互作用。口服给药后，递送系统在胃和小肠中保持稳定，随后到达富含肠道细菌的结肠段后，BBR突然释放。细菌产生的酶降解纳米颗粒，导致BBR直接暴露于肠道菌群。在高脂饮食诱导的肥胖仓鼠中，BBR-CS / PT-NP干预可显着高于BBR-CS / PT-NP干预，抑制体重增加和脂肪沉积，降低血浆脂质和葡萄糖水平，改善炎症状况和胰岛素抵抗，减轻肝脂肪变性。纯BBR可以。该机制可能归因于BBR和肠道菌群之间增强的相互作用。结果为靶向肠道菌群以改善代谢紊乱的药物递送提供了新的概念验证。

著录项

  • 来源
    《Advanced Functional Materials》 |2019年第14期|1808197.1-1808197.16|共16页
  • 作者

    Guo Hui-Hui; Ma Chen; Zheng Wen-Sheng; Luo Yang; Li Cong; Li Xiao-Lin; Ma Xiao-Lei; Feng Chen-Lin; Zhang Ting-Ting; Han Yan-Xing; Luo Zhi-Gang; Zhan Yun; Li Rui; Wang Lu-Lu; Jiang Jian-Dong;

  • 作者单位

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing 100021, Peoples R China|Peking Union Med Coll, Beijing 100021, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

    Chinese Acad Med Sci, Inst Mat Med, Beijing City Key Lab Drug Delivery Technol & Nove, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China|Peking Union Med Coll, Beijing 100050, Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号